<DOC>
	<DOCNO>NCT00079391</DOCNO>
	<brief_summary>This study evaluate safety effectiveness stem cell transplantation donor 's T cell ( type lymphocyte , white blood cell ) remove add back . Certain patient bone marrow malignancy undergo transplantation donate stem cell generate new normally function bone marrow . However , T-cells donor may see patient 's cell foreign mount immune response reject , cause call `` graft-versus-host-disease '' ( GVHD ) . Therefore , protocol , T-cells remove donor cell prevent complication . However , T-cells important fight viral infection well remain malignant cell ( call graft-versus-leukemia effect ) , donor T-cells give patient ( add back ) later time transplant provide need immunity less risk cause GVHD . Patients 10 55 year age acute chronic leukemia , myelodysplastic syndrome , myeloproliferative syndrome may eligible study . Prospective participant donor screen medical history physical examination , blood test ( include test match genetic compatibility ) , breathe test , chest sinus x-rays , test heart function . They also undergo bone marrow biopsy aspiration . For procedure , do local anesthetic , tablespoon bone marrow withdrawn needle insert hipbone . They undergo apheresis collect lymphocytes research study . This procedure involve collect blood needle arm , similar donate unit blood . The lymphocyte separate remove cell separator machine , rest blood return needle arm . Before treatment begin , patient central intravenous line ( flexible plastic tube ) place vein chest . This line remain place stem cell transplant recovery period draw transfuse blood , give medication , infuse donate cell . Preparation transfusion include high-dose radiation chemotherapy . Patients undergo total body irradiation 8 dos give two 30-minute session day 4 day . Eight day transplant , begin take fludarabine , 3 day procedure start cyclophosphamide .</brief_summary>
	<brief_title>Stem Cell Transplantation T-Cell Add-Back Treat Bone Marrow Malignancies</brief_title>
	<detailed_description>Bone marrow stem cell transplant study carry National Heart Lung &amp; Blood Institute ( NHLBI ) Bone Marrow Transplantation ( BMT ) Unit focus approach optimize stem cell lymphocyte dose order improve transplant survival increase graft-versus-leukemia effect . The aim create transplant condition permit rapid donor immune recovery without cause graft-versus-host disease ( GVHD ) use reduce post-transplant immunosuppression conjunction transplant deplete T cell fix low dose , threshold know associated GVHD . We find outcome transplant improve controlling stem cell ( CD34+ cell ) T lymphocyte ( CD3+ cell ) dose . We use `` Nexell Isolex 300i '' system obtain high CD34+ dos deplete lymphocyte fix CD3+ T cell dose 2 x 104/kg . The use cell separator monoclonal antibody cover Investigational Device Exemption . A persisting problem T cell deplete transplant slow acquisition full donor T cell engraftment ( T cell chimerism ) . Two previous protocol fail increase speed donor T cell chimerism . Patients mixed donor-recipient T cell population know high risk late graft rejection leukemic relapse transplant . Therefore , achievement full donor chimerism remain important therapeutic goal . In study test whether cyclosporine give day -6 +21 transplant significantly improve day 30 T cell chimerism ( principle end-point ) . The study also measure incidence acute chronic GVHD , day 100 transplant relate mortality , cytomegalovirus reactivation , relapse , disease-free survival appropriate safety stopping rule . This protocol follow closely previous study series . Three additional modification make however : 1 ) The first T cell add-back delay day 60 ( instead day 45 ) continue allow 45 day period without cyclosporine immunosuppression . 2 ) No day 100 T cell add-back give . ( In previous study many patient , protocol-defined reason , receive second transfusion evidence require ) . 3 ) Patients high-risk leukemias high relapse probability receive additional chemotherapy agent prior transplant use etoposide ( VP16 ) 60mg/kg improve chance remain remission .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>INCLUSION CRITERIA : RECIPIENT : 1 . Ages 1055 year inclusive ( less 56 ) 2 . Chronic myelogenous leukemia ( CML ) chronic phase 3 . Acute lymphoblastic leukemia ( ALL ) categories 1 . Adults first remission highrisk feature 2 . All second subsequent remission , primary induction failure , partially respond untreated relapse 4 . Acute myelogenous leukemia ( AML ) 1 . AML first remission Except AML good risk karyotype 2 . All AML second subsequent remission , primary induction failure resistant relapse 5 . Myelodysplastic syndrome category 1. refractory anemia transfusion dependence 2. refractory anemia excess blast 3. transformation acute leukemia , chronic myelomonocytic leukemia 6 . Myeloproliferative disorder transformation acute leukemia 7 . Chronic lymphocytic leukemia refractory fludarabine treatment bulky progressive disease thrombocytopenia ( less equal 100,000 /micro L ) anemia ( less equal 10g/dl ) due recent chemotherapy 8 . NonHodgkin 's lymphoma include Mantle cell lymphoma relapse refractory current chemotherapy monoclonal antibody treatment unsuitable autologous stem cell transplantation 9 . No major organ dysfunction preclude transplantation 10 . Diffusion capacity lung carbon monoxide ( DLCO ) great equal 60 % predict 11 . Left ventricular ejection fraction : great equal 40 % 12 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 13 . Able give inform consent 14 . Negative pregnancy test woman childbearing age INCLUSION CRITERIA : DONOR 1 . Human leukocyte antigen ( HLA ) 6/6 identical family donor 2 . Weight great equal 18 kg 3 . Age great equal 2 less equal 80 year old 4 . Fit receive granulocyte colony stimulate factor ( GCSF ) give peripheral blood stem cell ( normal blood count , normotensive , history stroke ) EXCLUSION CRITERIA : RECIPIENT 1 . Patient pregnant 2 . Age le 10 year 56 year 3 . Patients CML chronic phase 41 year imatinib mesylate ( STI571 ) treatment choice 4 . ECOG performance status 2 5 . Severe psychiatric illness 6 . Major anticipated illness organ failure incompatible survival BMT 7 . DLCO le 60 % predict 8 . Left ventricular ejection fraction : le 40 % 9 . Serum creatinine great 3mg/dl 10 . Serum bilirubin great 4 mg/dl 11 . HIV positive 12 . Debilitation age make risk intensive myeloablative therapy unacceptable EXCLUSION CRITERIA : DONOR 1 . Pregnant lactate 2 . Donor unfit receive GCSF undergo apheresis 3 . HIV positive 4 . Weight le 18 kg 5 . Age le 2 great 80 year 6 . Severe psychiatric illness</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Chronic Myelogenous Leukemia ( CML )</keyword>
	<keyword>Acute Lymphoblastic Leukemia ( ALL )</keyword>
	<keyword>Acute Myelogenous Leukemia ( AML )</keyword>
	<keyword>Chronic Lymphocytic Leukemia ( CLL )</keyword>
	<keyword>Myelodysplastic Syndromes ( MDS )</keyword>
	<keyword>Peripheral Blood Stem Cells</keyword>
	<keyword>Graft-Versus Leukemia/Myeloma</keyword>
	<keyword>Graft-Versus-Host Disease ( GVHD )</keyword>
	<keyword>Cyclosporine</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>Myeloproliferative Syndrome</keyword>
	<keyword>Non-Hodgkin Lymphoma</keyword>
</DOC>